dual dopamine D2/serotonin 5-HT1A/5-HT2A receptor inhibitors (Topharman Shanghai)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namedual dopamine D2/serotonin 5-HT1A/5-HT2A receptor inhibitors (Topharman Shanghai)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor antagonistsSerotonin 1a (5-HT1a) receptor antagonists
TargetsSerotonin 1a (5-HT1a) receptorDopamine D2 receptorSerotonin 2a (5-HT2a) receptor
Therapy Area/IndicationsSchizophrenia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesTopharman Shanghai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTopharman Shanghai Co Ltd
Active IndicationsN/A
Inactive IndicationsSchizophrenia

Other Information

ATC CodeN/A
Related LinksN/A